Literature DB >> 21749822

[A study protocol for clinical pathways based on integrative medicine for patients with acute myocardial infarction].

Lei Wang1, Li-Heng Guo, Jun Zhang, Xu-Jie Zhao, Min-Zhou Zhang.   

Abstract

BACKGROUND: Acute myocardial infarction (AMI) is one of the most common cardiovascular diseases. The clinical pathway is the therapeutic program for disease-specific treatment and its implementation may reduce both the duration and cost of the hospital stay. This study aims to construct and evaluate the efficacy of clinical pathways (CPs) based on integrated traditional Chinese and Western medicine for patients with AMI. METHODS AND
DESIGN: The clinical pathway of integrative medicine for AMI was constructed on the basis of syndrome evolvement surveys, literature research and expert consultation. Then, a non-randomized controlled, multicenter trial was designed to evaluate the efficacy and safety of the clinical pathway around the length of hospital stay, hospital expenses and the incidence of major cardiovascular events. This also allowed further exploration into the efficacy and safety of the clinical pathway for AMI based on traditional Chinese and Western medicine. DISCUSSION: The study firstly researched CPs based on the integrative medicine in hospitals of Chinese medicine and set up the key methods and skills for the construction of CPs of integrative medicine. This study will provide a powerful reference and direction for single-disease management reform under the healthcare system and set a good example for the improvement of integrative treatments. TRIAL REGISTRATION NUMBER: ChiCTR-TNRC-10000753.

Entities:  

Mesh:

Year:  2011        PMID: 21749822     DOI: 10.3736/jcim20110705

Source DB:  PubMed          Journal:  Zhong Xi Yi Jie He Xue Bao        ISSN: 1672-1977


  1 in total

1.  Whole-systems research in integrative inpatient treatment.

Authors:  Thomas Ostermann; Andre-Michael Beer; Vassya Bankova; Andreas Michalsen
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-24       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.